Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab

Ann Oncol. 2014 May;25(5):1073-4. doi: 10.1093/annonc/mdu058. Epub 2014 Feb 20.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology*
  • Female
  • Humans
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Prognosis
  • Receptor, ErbB-2 / metabolism*
  • Trastuzumab
  • Tumor Burden

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab